Rosa Wang
Research Subjects
Rosa Wang has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Martin Unverdorben
Daiichi Sankyo, Inc. , Basking Ridge , United States of America
2 shared publications - Xin Ye
Daiichi Sankyo Inc, Basking Ridge, NJ, USA
2 shared publications A Simpson
PRECISIONheor , Bethesda , United States of America
1 shared publication- Bernd Brüggenjürgen
Institute for Health Services Research and Technical Orthopedics, Orthopedic Department - Medical School Hannover (MHH) at DIAKOVERE Annastift Hospital, Hannover, Germany
1 shared publication - C Williams
PRECISIONheor , Bethesda , United States of America
1 shared publication - Cathy Chen
Global Specialty Medical Affairs, Daiichi Sankyo, Inc., Basking Ridge, NJ 07920, USA
1 shared publication
Latest Publications
- Open Access
- 24 May 2024
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 26 (Supplement)
Decoding definitions of major bleeding in retrospective observational studies on direct oral anticoagulants for atrial fibrillation: a targeted literature review
Background: Major bleeding is an adverse event associated with using direct oral anticoagulants (DOACs) for treatment of atrial fibrillation (AF). Incidence rates of major bleeding vary notably between randomised controlled trials (RCTs) and real-world evidence (RWE) studies. This may be attributable to inconsistent major bleeding definitions across RWE studies. RCTs commonly use the International Society on Thrombosis and Haemostasis (ISTH) major bleeding definition, including fatal bleeding, critical area/organ bleeding, bleeding requiring a blood transfusion of 2 or more units, and/or reductions in haemoglobin. These parameters may be absent in RWE studies, leading to utilisation of proxy definitions. Thus, the components used to define major bleeding in RWE studies remain unclear. Purpose: To examine major bleeding definitions via a targeted literature review of retrospective observational studies on patients with AF receiving DOACs in routine clinical practice. Methods: Studies of patients with AF receiving DOACs that were published between 2012 and 2022 were identified using keywords and MeSH terms in PubMed. Retrospective observational studies were screened for inclusion by title and abstract, and subsequently by full text. Articles were assessed for the types of databases and DOAC therapies studied. Components of major bleeding definitions were recorded and compared across database types. Results: Of 328 articles screened, 18 retrospective observational studies were included in this analysis. The most common data sources were claims data (n = 10), followed by electronic medical records (n = 4), and registry data (n = 4). Across studies, major bleeding incidence rates varied from 0.59 to 11.4 events per 100 person-years. Of the 6 components of major bleeding definitions identified, requiring hospitalisation (n = 12) was the most frequent (Figure), though is not essential per the ISTH definition. No articles used fatal bleeding as a component to define major bleeding. Approximately half of all articles used the component involvement of critical organ or site (n = 7). Requiring blood transfusion was used in 6 articles and only 4 used reduction in haemoglobin or haematocrit levels (none of these involved claims data). Conclusions: This targeted literature review of retrospective database studies of routine clinical practice decodes proxy use of ISTH major bleeding definitions. Claims data were the most common data source but lacked components describing fatal bleeding and haemoglobin levels. Further research is vital to assess the variation in reported major bleeding rates in RWE studies using proxy definitions in place of the ISTH definition.Figure
- 24 May 2024
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 26 (Supplement)
Open AccessDecoding definitions of major bleeding in retrospective observational studies on direct oral anticoagulants for atrial fibrillation: a targeted literature review
Background: Major bleeding is an adverse event associated with using direct oral anticoagulants (DOACs) for treatment of atrial fibrillation (AF). Incidence rates of major bleeding vary notably between randomised controlled trials (RCTs) and real-world evidence (RWE) studies. This may be attributable to inconsistent major bleeding definitions across RWE studies. RCTs commonly use the International Society on Thrombosis and Haemostasis (ISTH) major bleeding definition, including fatal bleeding, critical area/organ bleeding, bleeding requiring a blood transfusion of 2 or more units, and/or reductions in haemoglobin. These parameters may be absent in RWE studies, leading to utilisation of proxy definitions. Thus, the components used to define major bleeding in RWE studies remain unclear. Purpose: To examine major bleeding definitions via a targeted literature review of retrospective observational studies on patients with AF receiving DOACs in routine clinical practice. Methods: Studies of patients with AF receiving DOACs that were published between 2012 and 2022 were identified using keywords and MeSH terms in PubMed. Retrospective observational studies were screened for inclusion by title and abstract, and subsequently by full text. Articles were assessed for the types of databases and DOAC therapies studied. Components of major bleeding definitions were recorded and compared across database types. Results: Of 328 articles screened, 18 retrospective observational studies were included in this analysis. The most common data sources were claims data (n = 10), followed by electronic medical records (n = 4), and registry data (n = 4). Across studies, major bleeding incidence rates varied from 0.59 to 11.4 events per 100 person-years. Of the 6 components of major bleeding definitions identified, requiring hospitalisation (n = 12) was the most frequent (Figure), though is not essential per the ISTH definition. No articles used fatal bleeding as a component to define major bleeding. Approximately half of all articles used the component involvement of critical organ or site (n = 7). Requiring blood transfusion was used in 6 articles and only 4 used reduction in haemoglobin or haematocrit levels (none of these involved claims data). Conclusions: This targeted literature review of retrospective database studies of routine clinical practice decodes proxy use of ISTH major bleeding definitions. Claims data were the most common data source but lacked components describing fatal bleeding and haemoglobin levels. Further research is vital to assess the variation in reported major bleeding rates in RWE studies using proxy definitions in place of the ISTH definition.Figure
- Open Access
- 26 September 2022
- Published by Taylor & Francis in Future Cardiology
- Vol. 18 (10) , 787-796
Real-world Treatment Patterns and Stroke Risks Among Patients With Atrial Fibrillation in China
Aim: To describe patient characteristics, treatment patterns and stroke risks for patients with newly diagnosed atrial fibrillation (AF) in China. Patients & methods: Patients with AF were identifi... Plain language summary Atrial fibrillation (AF) is a condition characterized by a fast or irregular heartbeat that can lead to blood clots in the heart. This condition is common in China, but patie...
- 26 September 2022
- Published by Taylor & Francis in Future Cardiology
- Vol. 18 (10) , 787-796
Open AccessReal-world Treatment Patterns and Stroke Risks Among Patients With Atrial Fibrillation in China
Aim: To describe patient characteristics, treatment patterns and stroke risks for patients with newly diagnosed atrial fibrillation (AF) in China. Patients & methods: Patients with AF were identifi... Plain language summary Atrial fibrillation (AF) is a condition characterized by a fast or irregular heartbeat that can lead to blood clots in the heart. This condition is common in China, but patie...
- 26 October 2021
- Published by Springer Nature in PharmacoEconomics
- Vol. 40 (2) , 225-232
Is an Orphan Drug’s Cost-Effectiveness Associated with US Health Plan Coverage Restrictiveness?
Background and Objectives Orphan drugs’ high prices raise questions about whether their costs are worth their benefits. We examined the association between an orphan drug’s cost-effectiveness and health plan coverage restrictiveness. Methods We analyzed a dataset of US commercial health plan coverage decisions (information current as of 2019) for orphan drugs (n = 3298). We used multi-level random-effect logistic regression to examine the association between orphan drug cost-effectiveness and coverage restrictiveness. We identified cost-effectiveness estimates from the Tufts Medical Center Cost-Effectiveness Analysis Registry, and from the Institute for Clinical and Economic Review’s value assessments. We included only cost-effectiveness studies not funded by product manufacturers. We included the following independent variables: cancer indication, availability of alternatives, pediatric population, number of years since US Food and Drug Administration (FDA) approval, disease prevalence, annual cost, additional non-orphan indication, safety, and inclusion in a FDA expedited review program. Results Plans restricted drug coverage in 29.7% (n = 981) of decisions. Plans were more likely to restrict drugs with incremental cost-effectiveness ratios of $50,000–$175,000 per quality-adjusted life-year [QALY] (odds ratio = 1.855, p < 0.05), $175,000–$500,000 per QALY (odds ratio = 1.859, p < 0.05), and >$500,000 per QALY/dominated (odds ratio = 2.032, p < 0.01), compared to drugs with incremental cost-effectiveness ratios <$50,000 per QALY. Plans more often restricted drugs with non-cancer indications, having available alternatives, with more recent approval, in an FDA expedited review program, and for which the FDA additionally issued approval for a non-orphan disease. Plans more often restricted drugs with higher annual costs, and drugs indicated for higher prevalence diseases. All findings p < 0.05. Conclusions Among other factors, an orphan drug’s cost-effectiveness was associated with health plan drug coverage restrictiveness.
- 26 October 2021
- Published by Springer Nature in PharmacoEconomics
- Vol. 40 (2) , 225-232
Is an Orphan Drug’s Cost-Effectiveness Associated with US Health Plan Coverage Restrictiveness?
Background and Objectives Orphan drugs’ high prices raise questions about whether their costs are worth their benefits. We examined the association between an orphan drug’s cost-effectiveness and health plan coverage restrictiveness. Methods We analyzed a dataset of US commercial health plan coverage decisions (information current as of 2019) for orphan drugs (n = 3298). We used multi-level random-effect logistic regression to examine the association between orphan drug cost-effectiveness and coverage restrictiveness. We identified cost-effectiveness estimates from the Tufts Medical Center Cost-Effectiveness Analysis Registry, and from the Institute for Clinical and Economic Review’s value assessments. We included only cost-effectiveness studies not funded by product manufacturers. We included the following independent variables: cancer indication, availability of alternatives, pediatric population, number of years since US Food and Drug Administration (FDA) approval, disease prevalence, annual cost, additional non-orphan indication, safety, and inclusion in a FDA expedited review program. Results Plans restricted drug coverage in 29.7% (n = 981) of decisions. Plans were more likely to restrict drugs with incremental cost-effectiveness ratios of $50,000–$175,000 per quality-adjusted life-year [QALY] (odds ratio = 1.855, p < 0.05), $175,000–$500,000 per QALY (odds ratio = 1.859, p < 0.05), and >$500,000 per QALY/dominated (odds ratio = 2.032, p < 0.01), compared to drugs with incremental cost-effectiveness ratios <$50,000 per QALY. Plans more often restricted drugs with non-cancer indications, having available alternatives, with more recent approval, in an FDA expedited review program, and for which the FDA additionally issued approval for a non-orphan disease. Plans more often restricted drugs with higher annual costs, and drugs indicated for higher prevalence diseases. All findings p < 0.05. Conclusions Among other factors, an orphan drug’s cost-effectiveness was associated with health plan drug coverage restrictiveness.